sorafenib has been researched along with celastrol in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 885 | 1 | 741 |
| Protein | Taxonomy | sorafenib (IC50) | celastrol (IC50) |
|---|---|---|---|
| Telomerase reverse transcriptase | Homo sapiens (human) | 0.78 | |
| Ubiquitin carboxyl-terminal hydrolase 2 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Homo sapiens (human) | 6.8 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 8.41 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Homo sapiens (human) | 6.8 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 3.45 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.1 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.5667 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.25 | |
| Regulator of G-protein signaling 17 | Homo sapiens (human) | 6.1795 | |
| Ubiquitin carboxyl-terminal hydrolase 15 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Homo sapiens (human) | 6.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Kong, LC; Wei, P; Wu, SS; Xu, J; Zhang, R | 1 |
| Chen, B; Chen, J; Chen, X; Huang, S; Li, J; Peng, B; Tang, Y; Zheng, Y; Zhong, X; Zou, X | 1 |
2 other study(ies) available for sorafenib and celastrol
| Article | Year |
|---|---|
Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mice, Inbred C57BL; Pentacyclic Triterpenes; Signal Transduction; Sorafenib; Triterpenes; Xenograft Model Antitumor Assays | 2019 |
Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Forkhead Box Protein O1; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Middle Aged; Pentacyclic Triterpenes; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2021 |